Skip to main content

Table 7 Relationship between liver absorbed dose and liver response

From: Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio

   Liver dose (Gy)
Liver response Patients Average Median
No significant LFT change 25 12.4 9.4
Transient LFT abnormalities 7 37.0 23.9
Persistent LFT abnormalities 8 15.2 13.7